Fifty 1 Labs, Inc. (FITY)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: Nov 17, 2026
Fifty 1 Labs Revenue
Fifty 1 Labs had revenue of $47.00 in the quarter ending March 31, 2026, a decrease of -100.00%. This brings the company's total for the last twelve months to $47.00, down -100.00% year-over-year. In the fiscal year ending June 30, 2025, Fifty 1 Labs had annual revenue of $647.00 with 37.66% growth. That makes Fifty 1 Labs the 47,809th largest company in the world by revenue and 7,337th in the United States.
Revenue (ttm)
47.00
Revenue Growth
-100.00%
P/S Ratio
2,520.98
Revenue / Employee
23.50
Employees
2
Market Cap
118.49K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 647.00 | 177.00 | 37.66% |
| Jun 30, 2024 | 470.00 | -5.11M | -99.99% |
| Jun 30, 2010 | 5.11M | -305.13K | -5.64% |
| Jun 30, 2009 | 5.41M | 905.69K | 20.10% |
| Jun 30, 2008 | 4.51M | -2.44M | -35.11% |
| Jun 30, 2007 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2005 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ayurcann Holdings | 22.46M |
| Petros Pharmaceuticals | 5.11M |
| Endexx | 4.64M |
| Resonate Blends | 2.23M |
| CannLabs | 1.72M |
| ViaDerma | 44.69K |
| Pineapple Express Cannabis Company | 4.33K |
Fifty 1 Labs News
- 2 months ago - Fifty 1 Labs, Inc. Acquires MSK Signal Recovery Product Line to Accelerate Growth in the Peptide and Musculoskeletal Health Market - Accesswire
- 3 months ago - Fifty 1 Labs Outlines Planned U.S. Telehealth Peptide Services Platform - Accesswire
- 4 months ago - Fifty 1 Labs Announces Strategic Evolution into Peptide Biotechnology and Telehealth - Accesswire
- 7 months ago - Fifty 1 Labs, Inc. Accelerates Peptide Biotechnology Push into Musculoskeletal Health - Accesswire
- 7 months ago - Fifty 1 Labs, Inc. Eliminates 612 Million Shares from the Market - Accesswire
- 10 months ago - Fifty1 Labs, Inc. Clarifies Status Regarding Previously Announced Collaboration with LUNR Aerospace - GlobeNewsWire
- 1 year ago - Fifty 1 Labs Inc. Appoints Dr. Joel Gagnier as Chief Science Officer - GlobeNewsWire
- 1 year ago - Fifty 1 Labs Inc. Signs Letter of Intent to Acquire BioSpark AI Technologies Inc. - GlobeNewsWire